$HJLI News

Last published 1y ago

1y agoHJLI ADBEJaffe, Jonathan vs Adobe Inc. - AIA Trial, Institution GrantedUS Patent Trial and Appeal Board
5y agoHJLI NVNOenVVeno Medical Corporation Successfully Completes RebrandingACCESS NewswireCompany Now Trading Under Ticker Symbol "NVNO" IRVINE, CA / ACCESSWIRE / October 1, 2021 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, announced tod
5y agoHJLIHancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg ThalmannACCESS NewswireLive webinar followed by Q&A on Monday, September 27th at 1:00 PM ET with Robert Berman Chief Executive Officer of Hancock Jaffe Laboratories IRVINE, CA / ACCESSWIRE / September 24, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe"
5y agoHJLIHancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease ProgramsACCESS Newswire- Hancock Jaffe changing name to enVVeno Medical Corporation and ticker symbol to NASDAQ: NVNO, effective October 1, 2021 - - Development strategy to focus on venous disease and advancement of the VenoValve® - - Initiated development of second product
5y agoHJLIHancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021ACCESS NewswireConference call with live video webcast to be held on Tuesday, September 21st at 4:30 p.m. ET IRVINE, CA / ACCESSWIRE / September 15, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a developer of medical device
5y agoHJLIHancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ RulesACCESS NewswireIRVINE, CA / ACCESSWIRE / September 7, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has entered into a definitive agreement with a fund managed by
5y agoHJLIHancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual MeetingACCESS NewswireTwo-year VenoValve® data shows average improvements in reflux, disease manifestations and pain, of 63%, 60%, and 93%, respectively Patients with venous ulcers who experienced dramatic ulcer healing had no venous ulcer recurrences No safety issues occu
5y agoAAL AHPI EDU HJLI+1Thinking about buying stock in Hancock Jaffe Laboratories, Nikola Corp, New Oriental Education, Allied Healthcare, or American Airlines?PR NewswireNEW YORK, Aug. 3, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HJLI, NKLA, EDU, AHPI, and AAL. To
5y agoHJLIFDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValveACCESS Newswire- Goal of FDA Breakthrough Device Program is to speed up development by giving priority to devices that treat life-threatening or irreversibly debilitating conditions - Company preparing to begin SAVVE U.S. pivotal trial for VenoValve - VenoValve is a
5y agoHJLIHancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare ConferenceACCESS NewswireLive webcast on Tuesday, July 13th at 1:00 PM ET IRVINE, CA / ACCESSWIRE / July 8, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a developer of medical devices that restore cardiac and vascular health, today a
5y agoAZRX BOXL DBCCF DTII+5CEO Presenting on the Emerging Growth Conference on May 12. Register hereGlobeNewswireMIAMI, May 10, 2021 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies, announces the Schedule of the 7th Emergi
5y agoHJLIHancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International SymposiumACCESS NewswireIRVINE, CA / ACCESSWIRE / April 23, 2021 / (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI's first-in-human ® study in Bogota, Colombia, presented one year data this past week at the Charing Cross International Symposium. The Charing Cross International Symposium is the longes ...
5y agoHJLIFirst U.S. Patent Issues on Hancock Jaffe VenoValveACCESS Newswire(NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the United States Patent and Trademark Office (USPTO) has issued the first patent covering the company's VenoValve. The patent is entitled Implantable Vein Frame and is U.S. patent number 10,959,841.
5y agoHJLIHancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal TrialACCESS Newswire(NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational Device Exemption (IDE) application to begin the U.S. pivotal trial for the ®. The VenoValve is an implantable valve designed to restore proper directional blood flow for patients with Chronic Venous Insuf ...
5y agoHJLIHancock Jaffe Submits IDE Application to FDA for VenoValve U.S. Pivotal TrialACCESS Newswire(NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) seeking approval to begin a U.S. pivotal trial for the ®. The VenoValve is an implantable valve designed to restore proper directional blood flow for patients with Chronic V ...
5y agoHJLIFirst U.S. Patent Allowed on Hancock Jaffe VenoValveACCESS NewswireCompany Receives Notice of Allowance from U.S. Patent and Trademark Office
5y agoHJLIHancock Jaffe Completes $41 Million Public OfferingACCESS NewswireCapital Raise to Fund VenoValve U.S. Pivotal Trial
5y agoHJLIHancock Jaffe Laboratories Announces Pricing of Upsized $36 Million OfferingACCESS NewswireHancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced the pricing of its upsized underwritten public offering of units for gross proceeds of approximately $36 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the company.
5y agoHJLIHancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDAACCESS NewswireCompany to Move Forward with Application for VenoValve U.S. Pivotal Trial
5y agoHJLIHancock Jaffe Reports Two CoreoGraft Patients Have Reached 30 Day MilestoneACCESS NewswireElectrocardiograms Indicate Good Cardiac Function for Both Patients
5y agoHJLIHancock Jaffe Announces Significant Improvements in all Study Endpoints For Final VenoValve First-in-Human DataACCESS NewswirePatients Show Significant Improvements in Reflux, VCSS, and VAS Scores
5y agoHJLIHancock Jaffe Announces One Year Follow-up Data on Eleventh VenoValve PatientACCESS NewswireFinal Patient in First-in-Human Study Shows Significant Improvement at One Year
5y agoHJLIHancock Jaffe to Provide VenoValve and CoreoGraft Updates at Ladenburg Thalmann R&D Showcase Webinar on December 16, 2020ACCESS NewswireVenoValve and CoreoGraft Primary Investigators to Present at Webinar
5y agoHJLIHancock Jaffe Announces One Year Follow-up Data on Tenth VenoValve PatientACCESS NewswirePatient Shows Significant Improvement at One Year
5y agoHJLIHancock Jaffe Announces Reverse Stock SplitACCESS NewswireHancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1 for 25 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. Eastern time on November 30, 2020 and the Compan ...
5y agoHJLIHancock Jaffe's VenoValve(R) Results Featured in Journal of Vascular Surgery Venous and Lymphatic DisordersACCESS NewswirePreliminary First-in-Human Study Results Published in Peer-Reviewed Journal
6y agoHJLIHancock Jaffe Announces Date for VenoValve Pre-IDE Meeting with FDAACCESS NewswireMeeting with FDA Set for December 22
6y agoHJLIHancock Jaffe Reports Successful Completion of First CoreoGraft Heart Bypass SurgeryACCESS NewswireFirst CoreoGraft Recipient Discharged from the Hospital
6y agoHJLIHancock Jaffe Submits VenoValve Pre-IDE Filing to FDAACCESS NewswireRequests Pre-IDE Meeting with FDA
6y agoHJLIHancock Jaffe Announces One Year Follow-up Data on Ninth VenoValve PatientACCESS NewswirePatient Continues to Show Significant Improvement at One Year
6y agoHJLIHancock Jaffe to Begin CoreoGraft First-in-Human StudyACCESS NewswireFirst Two Surgeries Scheduled to Take Place by End of October
6y agoHJLIHancock Jaffe Laboratories, Inc. Announces Pricing of $5.1 Million Registered Direct Offering Priced at the MarketACCESS NewswireHancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced the pricing of a registered direct offering of $5.1 million of its common stock and warrants to purchase shares of common stock in a concurrent private placement. The combined purchase price for one share of common stock and one warrant to purchase one share of c ...
6y agoHJLIHancock Jaffe Announces Positive Nasdaq Listing DeterminationACCESS NewswireExtension Granted for Continued Listing
6y agoHJLIHancock Jaffe Announces One Year Follow-up Data on Two Additional VenoValve PatientsACCESS NewswireVenoValve Patients Continue to Show Significant Improvement at One Year
6y agoHJLIHancock Jaffe Regains Compliance with Nasdaq Stockholder\'s Equity RuleACCESS NewswireHancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that HJLI has received formal notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has evidenced full compliance with the stockholders' equity requirement for the continued listing of its shares on The Nasdaq Capital Market and, as a result, ...
6y agoHJLIHancock Jaffe Receives Permission to Proceed with First-in-Human CoreoGraft StudyACCESS NewswirePatient Selection to Begin Immediately for CoreoGraft Study
6y agoHJLIHancock Jaffe Laboratories Announces Closings of $6.2 Million Offerings Including Full Exercise of Over-Allotment OptionACCESS NewswireHancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced the closings of an underwritten public offering, the full exercise of the underwriter's over-allotment option, and a private placement, for total gross proceeds of approximately $6.2 million, prior to deducting underwriting discounts, placement agent fees, and of ...
6y agoHJLIHancock Jaffe Laboratories Announces Pricing of $5.6 Million OfferingACCESS NewswireHancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced the pricing of a $5.6 million offering, which consisted of an underwritten public offering of units and a private placement of units for gross proceeds of approximately $5.6 million, prior to deducting underwriting discounts and commissions and offering expenses ...
6y agoHJLIHancock Jaffe Announces Registered Direct Offering Priced At MarketACCESS NewswireHancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $1.333 million of its common stock in a registered direct offering and warrants to purchase shares of common stock in a con ...
6y agoHJLIHancock Jaffe Announces Intention to Merge with Catheter PrecisionACCESS NewswireCompanies Sign Non-Binding Letter of Intent to Merge
6y agoHJLIHancock Jaffe Announces Plans for CoreoGraft First-in-Human StudyACCESS NewswireCoreoGraft Study Approved by the Superintendent of Health of the National Health Council of Paraguay
6y agoHJLIHancock Jaffe Announces One Year Follow-up Data on VenoValve PatientsACCESS NewswireVenoValve Patients Continue to Show Significant Improvement at One Year
6y agoHJLIHancock Jaffe Announces Registered Direct OfferingACCESS NewswireHancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $1 million of its common stock in a registered direct offering and warrants to purchase shares of common stock in a concurr ...